Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Immunovant (NASDAQ:IMVT) announced its quarterly earnings data on Friday. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11, FiscalAI reports. During the same quarter last year, the firm posted ($0.76) earnings per share.

Here are the key takeaways from Immunovant’s conference call:

• Phase 2 cutaneous sarcoidosis: BREPA 45 mg produced a ~21.6?point placebo?adjusted CSAMI improvement with a 100% ?10?point responder rate, rapid separation vs placebo, supportive PROs and no SAEs reported in the study.
• Development and catalyst cadence is heavy in 2026 — a phase 3 program for cutaneous sarcoidosis will start this year, an NDA is filed for dermatomyositis, NIU phase 3 readout is expected in H2 2026, and multiple other trials (mosliciguat, DTT?RA, 1402 CLE) are fully enrolled or nearing data.
• Financially fortified: Roivant reported a consolidated cash balance of about $4.5 billion and non?GAAP net loss of $167M for the quarter, which management says provides runway to multiple near?term development and potential launches.
• Commercial opportunity: Management views BREPA as a multi?indication orphan franchise (DM, NIU, CS) with high unmet need and expects orphan pricing levers if phase 3 results mirror the strong phase 2 outcomes.
• JV/accounting note: Priovant is 25% owned by Pfizer and Roivant will fully consolidate Priovant’s results while recording Pfizer’s share as a below?the?line minority interest; Pfizer’s early dilution protections are exhausted, so future capital raises could require Pfizer to match or lead to dilution.

Immunovant Trading Up 12.4%

Shares of NASDAQ:IMVT opened at $27.05 on Friday. The company has a market capitalization of $4.74 billion, a PE ratio of -9.52 and a beta of 0.54. Immunovant has a twelve month low of $12.72 and a twelve month high of $27.80. The firm has a 50 day simple moving average of $25.61 and a 200-day simple moving average of $20.75.

Analyst Ratings Changes

Several research analysts recently commented on IMVT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research note on Friday, January 9th. Guggenheim reiterated a “buy” rating and issued a $41.00 price objective on shares of Immunovant in a research note on Thursday, December 18th. The Goldman Sachs Group boosted their price objective on Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Truist Financial raised their target price on shares of Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Finally, Wolfe Research upgraded shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Immunovant currently has an average rating of “Moderate Buy” and an average target price of $30.78.

Insider Transactions at Immunovant

In other Immunovant news, Director Douglas J. Hughes sold 15,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $23.24, for a total value of $348,600.00. Following the completion of the transaction, the director owned 120,773 shares in the company, valued at $2,806,764.52. This represents a 11.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tuyl Christopher Van sold 10,813 shares of Immunovant stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $26.91, for a total value of $290,977.83. Following the sale, the insider owned 149,930 shares in the company, valued at $4,034,616.30. This trade represents a 6.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 63,868 shares of company stock worth $1,538,470. Insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Immunovant by 8.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock valued at $708,000 after buying an additional 3,348 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Immunovant by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after acquiring an additional 329,354 shares during the last quarter. Strs Ohio acquired a new position in shares of Immunovant in the 1st quarter valued at $27,000. Legal & General Group Plc raised its position in Immunovant by 6.9% in the 2nd quarter. Legal & General Group Plc now owns 77,296 shares of the company’s stock valued at $1,237,000 after purchasing an additional 5,010 shares during the last quarter. Finally, Invesco Ltd. raised its position in Immunovant by 20.7% in the 2nd quarter. Invesco Ltd. now owns 66,750 shares of the company’s stock valued at $1,068,000 after purchasing an additional 11,438 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.